136 related articles for article (PubMed ID: 38490135)
1. Generation of three myotonic dystrophy type 1 patient iPSC lines (CBRCULi018-A, CBRCULi019-A, CBRCULi020-A) derived from lymphoblastoid cell lines for disease modelling and therapeutic research.
Pierre M; Jauvin D; Puymirat J; Boutjdir M; Chahine M
Stem Cell Res; 2024 Apr; 76():103375. PubMed ID: 38490135
[TBL] [Abstract][Full Text] [Related]
2. Lymphoblastoid cell lines derived from iPSCs of a myotonic dystrophy type 1 patient carrying 700 CTG repeats (CBRCULi007-A) and a control (CBRCULi006-A).
Chahine M; Jauvin D; Pierre M; Puymirat J; Boutjdir M
Stem Cell Res; 2023 Sep; 71():103148. PubMed ID: 37352653
[TBL] [Abstract][Full Text] [Related]
3. Generation of four myotonic dystrophy type 1 patient iPSC lines (CBRCULi002-A, CBRCULi003-A, CBRCULi004-A, CBRCULi005-A) and a control (CBRCULi001-A) derived from lymphoblastoids cell lines.
Jauvin D; Pierre M; Boutjdir M; Puymirat J; Chahine M
Stem Cell Res; 2023 Mar; 67():103037. PubMed ID: 36739767
[TBL] [Abstract][Full Text] [Related]
4. Lymphoblastoids cell lines - Derived iPSC line from a 26-year-old myotonic dystrophy type 1 patient carrying (CTG)
Martineau L; Racine V; Benichou SA; Puymirat J
Stem Cell Res; 2018 Jan; 26():103-106. PubMed ID: 29274549
[TBL] [Abstract][Full Text] [Related]
5. Generation of induced pluripotent stem cell lines from pediatric patients with congenital myotonic dystrophy (CBRCULi012-A and CBRCULi013-A) and age-matched controls (CBRCULi010-A and CBRCULi011-A).
De Serres-Bérard T; Jauvin D; Puymirat J; Chahine M
Stem Cell Res; 2023 Oct; 72():103234. PubMed ID: 37871474
[TBL] [Abstract][Full Text] [Related]
6. Generation of induced pluripotent stem cell line (ZZUi015-A) from a DM1 patient with cataract.
Li T; Sun H; Wang Z; Zhang Q; Chen N; Zhang K; Wang Y; Xu Y
Stem Cell Res; 2022 Jan; 58():102623. PubMed ID: 34915310
[TBL] [Abstract][Full Text] [Related]
7. Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells.
Dastidar S; Ardui S; Singh K; Majumdar D; Nair N; Fu Y; Reyon D; Samara E; Gerli MFM; Klein AF; De Schrijver W; Tipanee J; Seneca S; Tulalamba W; Wang H; Chai YC; In't Veld P; Furling D; Tedesco FS; Vermeesch JR; Joung JK; Chuah MK; VandenDriessche T
Nucleic Acids Res; 2018 Sep; 46(16):8275-8298. PubMed ID: 29947794
[TBL] [Abstract][Full Text] [Related]
8. Length-dependent CTG·CAG triplet-repeat expansion in myotonic dystrophy patient-derived induced pluripotent stem cells.
Du J; Campau E; Soragni E; Jespersen C; Gottesfeld JM
Hum Mol Genet; 2013 Dec; 22(25):5276-87. PubMed ID: 23933738
[TBL] [Abstract][Full Text] [Related]
9. Generation of a lymphoblastoid-derived induced pluripotent stem cell line (CBRCULi015-A) from a patient with congenital myotonic dystrophy.
De Serres-Bérard T; Jauvin D; Pouliot V; Puymirat J; Chahine M
Stem Cell Res; 2024 Jun; 77():103430. PubMed ID: 38704930
[TBL] [Abstract][Full Text] [Related]
10. Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program.
Johnson NE; Butterfield RJ; Mayne K; Newcomb T; Imburgia C; Dunn D; Duval B; Feldkamp ML; Weiss RB
Neurology; 2021 Feb; 96(7):e1045-e1053. PubMed ID: 33472919
[TBL] [Abstract][Full Text] [Related]
11. Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
Mootha VV; Hansen B; Rong Z; Mammen PP; Zhou Z; Xing C; Gong X
Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4579-4585. PubMed ID: 28886202
[TBL] [Abstract][Full Text] [Related]
12.
Visconti VV; Macrì E; D'Apice MR; Centofanti F; Massa R; Novelli G; Botta A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373276
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome Analysis Reveals Altered Inflammatory Pathway in an Inducible Glial Cell Model of Myotonic Dystrophy Type 1.
Azotla-Vilchis CN; Sanchez-Celis D; Agonizantes-Juárez LE; Suárez-Sánchez R; Hernández-Hernández JM; Peña J; Vázquez-Santillán K; Leyva-García N; Ortega A; Maldonado V; Rangel C; Magaña JJ; Cisneros B; Hernández-Hernández O
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33530452
[TBL] [Abstract][Full Text] [Related]
14. CpG Methylation, a Parent-of-Origin Effect for Maternal-Biased Transmission of Congenital Myotonic Dystrophy.
Barbé L; Lanni S; López-Castel A; Franck S; Spits C; Keymolen K; Seneca S; Tomé S; Miron I; Letourneau J; Liang M; Choufani S; Weksberg R; Wilson MD; Sedlacek Z; Gagnon C; Musova Z; Chitayat D; Shannon P; Mathieu J; Sermon K; Pearson CE
Am J Hum Genet; 2017 Mar; 100(3):488-505. PubMed ID: 28257691
[TBL] [Abstract][Full Text] [Related]
15. Myotonic dystrophy type 1 patient-derived iPSCs for the investigation of CTG repeat instability.
Ueki J; Nakamori M; Nakamura M; Nishikawa M; Yoshida Y; Tanaka A; Morizane A; Kamon M; Araki T; Takahashi MP; Watanabe A; Inagaki N; Sakurai H
Sci Rep; 2017 Feb; 7():42522. PubMed ID: 28211918
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of DMPK: correlation with CTG repeat expansion and fibre type composition in myotonic dystrophy type 1.
Salvatori S; Fanin M; Trevisan CP; Furlan S; Reddy S; Nagy JI; Angelini C
Neurol Sci; 2005 Oct; 26(4):235-42. PubMed ID: 16193250
[TBL] [Abstract][Full Text] [Related]
17. MSH2 knock-down shows CTG repeat stability and concomitant upstream demethylation at the DMPK locus in myotonic dystrophy type 1 human embryonic stem cells.
Franck S; Barbé L; Ardui S; De Vlaeminck Y; Allemeersch J; Dziedzicka D; Spits C; Vanroye F; Hilven P; Duqué G; Vermeesch JR; Gheldof A; Sermon K
Hum Mol Genet; 2021 Jan; 29(21):3566-3577. PubMed ID: 33242073
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetics of congenital myotonic dystrophy.
Lanni S; Pearson CE
Neurobiol Dis; 2019 Dec; 132():104533. PubMed ID: 31326502
[TBL] [Abstract][Full Text] [Related]
19. Myotonic dystrophy type 1: role of CCG, CTC and CGG interruptions within DMPK alleles in the pathogenesis and molecular diagnosis.
Santoro M; Masciullo M; Silvestri G; Novelli G; Botta A
Clin Genet; 2017 Oct; 92(4):355-364. PubMed ID: 27991661
[TBL] [Abstract][Full Text] [Related]
20. Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy.
Gao Y; Guo X; Santostefano K; Wang Y; Reid T; Zeng D; Terada N; Ashizawa T; Xia G
Mol Ther; 2016 Aug; 24(8):1378-87. PubMed ID: 27203440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
